Cholangitis

Primary biliary cholangitis (PBC), a rare autoimmune liver disease, shares 10 genetic risk factors with inflammatory bowel disease (IBD), a group of inflammatory conditions…

Researchers at the University of California San Diego (UCSD) have created a molecule, named antisense oligonucleotide (ASO) 56, that is able to potently reduce liver…

Ascletis Pharma will not to pursue further clinical testing of its experimental oral therapy ASC42 for adults with primary biliary cholangitis (PBC). The…

Elafibranor, an oral molecule under regulatory review as a new second-line treatment for adults with primary biliary cholangitis (PBC), may become the first candidate…

The U.S. Food and Drug Administration (FDA) has granted fast track designation to LB-P8, LISCure Biosciences’ experimental live bacterium product that is headed toward…

Golexanolone, Umecrine Cognition’s investigational oral therapy, was generally safe and well tolerated in adults with primary biliary cholangitis (PBC) and clinically significant…

The U.S. Food and Drug Administration (FDA) agreed to review an application seeking full and formal approval of Ocaliva (obeticholic acid) as a…

LISCure Biosciences will launch a Phase 2 trial in the United States to evaluate the safety and effectiveness of LB-P8, its live bacterium candidate…

Daily treatment with seladelpar, CymaBay Therapeutics’ investigational oral candidate for people with primary biliary cholangitis (PBC), was shown to normalize liver biomarkers and…

Chemomab Therapeutics has been awarded patents in Brazil and Israel covering CM-101, the company’s experimental therapy that’s currently being tested in a Phase…